Erivance BCC (N = 96) | EAS (N = 95) | ||||||
---|---|---|---|---|---|---|---|
laBCC | mBCC | laBCC | mBCC | ||||
BCCNS (n = 21) | Non-BCCNS (n = 42) | Non-BCCNS (n = 33) | BCCNS (n = 12) | Non-BCCNS (n = 44) | BCCNS (n = 6) | Non-BCCNS (n = 33) | |
BORR, n (%) [95 % CI] | 17 (81) [58–95] | 21 (50) [34–66] | 15 (46) [28–64] | 4 (33) [10–65] | 22 (50) [35–65] | 3 (50) [12–88] | 9 (27) [13–46] |
Complete response | 8 (38) | 12 (29) | 0 | 1 (8) | 5 (11) | 2 (33) | 0 |
Partial response | 9 (43) | 9 (21) | 15 (46) | 3 (25) | 17 (39) | 1 (17) | 9 (27) |
Stable disease | 3 (14) | 12 (29) | 15 (46) | 6 (50) | 21 (48) | 3 (50) | 17 (52) |
Progressive disease | 1 (5) | 5 (12) | 2 (6) | 2 (17) | 0 | 0 | 3 (9) |
Not evaluable or missing | 0 | 4 (10) | 1 (3) | 2 (17) | 1 (2) | 0 | 4 (12) |